Check out our piece Nature Genetics 👇🥳

Addressing the mechanistic gaps & strategies forward to investigate the full therapeutic potential & benefits of inhibiting APOBEC mutagenesis in cancer

Fab collab 🙏 Weitzman Lab Abby Green John Maciejowski

nature.com/articles/s4158…

We are really excited to present our work describing over 23,000 liquid biopsy cases to understand the relationship between ctDNA shed and the detection of actionable alterations on plasma testing. Here is a tweetorial describing our work.

A pleasure meeting many of our colleagues at the fall Polyethnic-1000 Consortium Meeting yesterday. We look forward to seeing you at our next meeting in the spring! NY Genome Center

Looking forward to hosting our first in-person P1000 Consortium Meeting this afternoon at NY Genome Center! Moderated by Dr. Harold Varmus and featuring speakers Nicolas Robine (@notSoJunkDNA) and Vijay Sankaran (@bloodgene).

I have some thoughts on the new eLife policy

To say I am proud of this important move in service of science and all of the resolute people @elife who worked *tirelessly* to make it happen is a massive understatement

I will be speaking on #Treatment Updates and #clinicaltrials for #PancreaticCancer in an webinar for patients and family members in honor for Pancreatic Cancer Awareness month. We have a great program lined up! Dr. Allyson Ocean National Pancreas Foundation Let's Win Pancreatic Cancer 💜 WCM GI Cancer PanCAN AACR

I saw someone with #BRCA1 #breastcancer who didn’t know she was at risk for #PancreaticCancer . She only thought she could get #ovariancancer This is a very sad, missed opportunity for screening. #PancChat

Dear colleagues, we need support to increase accrual in this important phase 3 EA8192 trial! OncoAlert Jean Hoffman-Censits Suzanne Cole, MD Rafee Talukder Sarah P. Psutka MD MS ECOG-ACRIN Cancer Research Group SWOG Cancer Research Network Alliance for Clinical Trials in Oncology NCI CCR GU Malignancies rohit jain Arturo Loaiza-Bonilla, MD MSEd Shilpa Gupta Eugene Pietzak Dr. Bishoy M. Faltas Bladder Cancer Advocacy Network

#BladderCancer occurs when cells in the bladder grow out of control. #Immunotherapy , #Chemotherapy , #RadiationTherapy , #Surgery , and #ClinicalTrials may be treatment options depending on the specifics of your #cancer : bit.ly/3E9E941

In a Review now online, Dr. Nicole Kuderer 🌎🇺🇸🇪🇺🇺🇦💛💙🌏, Aakash Desai, MD, MPH, Maryam Lustberg MD MPH and Gary Lyman 🇺🇸🇪🇺🇺🇦💛💙 explain the most common acute toxicities in patients with cancer receiving chemotherapy and discuss management options: nature.com/articles/s4157…

FORT-1 tested rogaratinib vs chemotherapy in FGFR1/3 +ve(RNA) platinum refractory UC. 600 patients screened 175 randomised (60% biomarker +ve?) Efficacy results showed regimens were very similar. Erdafitinib has a better biomarker plan. Randomised trials with erda may still be OK

🙌 Enfortumab vedotin + pembro as 1st-line tx for metastatic #UrothelialCancer yields response rate of 73.3%, duration of response 25.6 mo, overall survival 26.1 mo. 👉 fal.cn/3sEjU #JCO #blcsm #kcsm #gucsm Jonathan Rosenberg MD

The brilliant expert on stage on his favorite topic! Thanks Pavlos Msaouel for moving this field forward and helping patients!

42: the answer to everything? We are so excited to share our study led by the fantastic Lukas & Tobias Neumann, which identified HPV42 as an oncogenic #virus that causes skin #cancer & a germ cell-like program conserved in all HPV+ cancers. 🧵👇/1
doi.org/10.1158/2159-8…

It’s spatial profiling day on bioRxiv!
Now 10x Genomics out with a preprint on integrated single cell, spatial and in situ analysis of FFPE tissue. Very excited by the extension of these high dimensional technologies to archival samples!
biorxiv.org/content/10.110…